by Peter Ciszewski | Sep 26, 2017
Scientists may have developed the first targeted, oral, tumor-type agnostic therapy – a cancer medicine that works comparably well across many kinds of cancer, regardless of patient age. In clinical trials of adults and children with 17 different types of advanced...
by Peter Ciszewski | Sep 26, 2017
A randomized clinical trial of 766 patients shows that a simple intervention — a web-based tool that enables patients to report their symptoms in real time, triggering alerts to clinicians — can have major benefits, including longer survival. Patients...
by Peter Ciszewski | Sep 26, 2017
In an early clinical trial, 33 out of 35 (94%) patients had clinical remission of multiple myeloma upon receiving a new type of immunotherapy, chimeric antigen receptor (CAR) T cells targeting B-cell maturation protein (BCMA). Most patients had only mild side effects....
by Peter Ciszewski | Sep 26, 2017
Genomic testing of tumor samples can enable personalized treatment selection, where targeted treatments are matched to genetic changes in the tumor. Although a growing number of patients with advanced cancers receive some genomic testing, comprehensive genomic testing...
by Peter Ciszewski | Sep 26, 2017
Sickle Cell Disease and Beta-thalassemia are two severe diseases that are caused by defects in the beta-globin protein in hemoglobin, present in red blood cells. Patients born with Sickle Cell Disease and Beta-thalassemia do not have symptoms when they are first born...
